SCHEMBL29935520

SCHEMBL29935520

FC(F)(F)c1ccc(O[C@H]2CCN(c3ccc(-c4ccccc4Cl)cc3)C2)nc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 2/20 0.52
LIPE Q05469 6/20 0.46
KMT2A Q03164 1/20 0.43
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
SCD O00767 1/20 0.41
HSD11B1 P28845 3/20 0.40
MET P08581 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
FPR2 P25090 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
LPL P06858 1/20 0.39
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935534 0.88 LIPG (0.59) LIPGLIPECYP2C9CYP2C19GAA
Ammonia Solution, Strong SCHEMBL23703282 0.87 LIPG (0.58) LIPGLIPECYP2C9CYP2C19GAA
SCHEMBL23708520 0.86 LIPG (0.54) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL23708512 0.86 LIPG (0.54) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL29994651 0.86 LIPG (0.54) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL23708527 0.85 LIPG (0.58) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL23708524 0.85 LIPG (0.56) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL23708322 0.85 LIPG (0.56) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL23702971 0.85 LIPG (0.58) LIPGLIPEKMT2ACYP2C9CYP2C19
SCHEMBL23708319 0.85 LIPG (0.58) LIPGLIPEKMT2ACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 LIPG 1423/4885LIPE 3173/4885KMT2A 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.